South Korea Fabry Disease Market Insight
Published: 23 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
Due to novel treatments and sophisticated diagnostics, the South Korean fabric disease market is predicted to increase at a compound annual growth rate (CAGR) of 6.59% between 2025 and 2035.
South Korea Fabry Disease Market Insights Forecasts to 2035
- The South Korea Fabry Disease Market Size Was Estimated USD 47.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.59% from 2025 to 2035
- The South Korea Fabry Disease Market Size is Expected to rise around USD 90.5 Million by 2035
Notable Insights for the South Korea Fabry Disease Market
- According to treatment segmentation, the South Korean fabric market is dominated by Enzyme Replacement Therapy (ERT), while chaperone therapy is expanding because of increased reimbursement for oral choices.
- According to end-user segmentation, hospitals dominate the South Korean market for Fabry disease, while homecare settings are becoming more popular for enzyme replacement therapy, which provide chronic patients with convenience.
- In 2026, the South Korean government reduced patient co-pay from 10% and shortened the time it takes for a medicine to be approved to 100 days, expanding insurance coverage for 1,387 rare disorders.
Download the eBook (ToC)
- Government programs that supported 1,150 genetic tests in 2026, together with commercial R&D partnerships and profits from novel treatments, brought substantial money to the South Korean Fabry disease industry.
Why Buy This Report
- This study is helpful for people who want to make investment decisions. We can learn about what happened in the past, what is happening now and what might happen from 2025 to 2035.
- The research is very detailed. It helps us understand how the demand for certain products is changing in the South Korean fabric disease market. It also helps us find areas that are growing fast.
- With application-wise analysis including ERT, chaperone therapy, and other therapies, businesses may effectively target the most profitable areas, allowing for exact market positioning.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea fabry disease market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Fabry Disease Market
- Hanmi Pharmaceutical Co., Ltd.
- GC Biopharma Corp.
- Sanofi Korea
- Kwangdong Pharmaceutical
- Hanok Pharmaceutical
- Amicus Therapeutics
- Chiesi Farmaceutici
- Takeda Pharmaceutical
- Pfizer
- Novartis
Recent Developments:
- In November 2024 the company said it will keep working on helping people with diseases and making new treatments available to them by starting new projects to help patients with rare illnesses and making special medicines.
- In October 2024 the company got better at making treatments for people with diseases like Fabry disease by working with another company to do more research on special medicines for rare diseases.
Market Segmentation:
South Korea Fabry Disease Market, By Treatment Type
- Enzyme Replacement Therapy
- Chaperone Therapy
- Others
South Korea Fabry Disease Market, By End-User
- Hospitals
- Homecare
- Specialty Clinics
South Korea Fabry Disease Market, By Disease Type
- Classic Fabry Disease
- Atypical Late-Onset Fabry Disease
Expert Views:
The market for Fabry disease in South Korea is anticipated to witness steady growth owing to the rising levels of awareness, early diagnosis, increasing availability of treatment via enzyme replacement and chaperones, and presence of favorable rare disease policies. Ongoing developments in precision medicine and orphan drugs development are set to positively impact treatment and market dynamics till 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting